SAN DIEGO, Dec. 17, 2014 /PRNewswire/ -- BOTTINI & BOTTINI, INC. (http://www.bottinilaw.com) today announced that a class action has been commenced in the United States District Court for the Central District of California on behalf of persons who sold Allergan, Inc. (NYSE: AGN) common stock between February 25, 2014 and April 21, 2014 (the "Class Period").

If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from December 17, 2014. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff's counsel, Frank A. Bottini or Albert Y. Chang of Bottini & Bottini, at (858) 914-2001, or via e-mail at fbottini@bottinilaw.com or achang@bottinilaw.com. If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at http://www.bottinilaw.com/cases/ valeant/. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

The complaint charges defendants Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, AGMS, Inc., Pershing Square Capital Management L.P., William A. Ackman, PS Management GP, LLC, and PS Fund 1, LLC ("Defendants") with violations of Sections 14(e) and 20A of the Securities Exchange Act of 1934, as amended.

Plaintiff alleges that Valeant unlawfully tipped Pershing Square about its plan to make a tender offer for Allergan, with Pershing Square then trading on such material, non-public information by buying an approximately 9.7% stake in Allergan during the Class Period without first disclosing Valeant's plan to pursue a tender offer to acquire Allergan at a significant premium.

When Valeant first disclosed its desire to pursue an acquisition of Allergan to the stock market on April 22, 2014, Allergan's stock price soared, rising from a closing price the previous day of $141.88 to close at $163.51 on April 22, 2014 on huge volume of over 32 million shares - ten times Allergan's average daily trading volume during the Class Period.

Plaintiff seeks to recover damages on behalf of all persons who sold Allergan stock between February 25, 2014 and April 21, 2014, inclusive. Plaintiff alleges that class members were damaged by selling their Allergan stock during the Class Period at prices that did not reflect Valeant's anticipated tender offer to acquire Allergan at a significant premium. The plaintiff is represented by Bottini & Bottini, which specializes in representing investors and has extensive experience in prosecuting securities class actions.

Located in San Diego, California, Bottini & Bottini represents shareholders across the country in contingency-based securities class action litigation. The firm has obtained many multi-million dollar recoveries for shareholders. Please visit http://www.bottinilaw.com for more information.

Contact:

BOTTINI & BOTTINI, INC.
Albert Y. Chang
Telephone: (858) 914-2001
E-mail: achang@bottinilaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bottini--bottini-inc-files-class-action-lawsuit-on-behalf-of-persons-who-sold-allergan-stock-between-february-25-2014-and-april-21-2014-300010996.html

SOURCE BOTTINI & BOTTINI INC.